News

Key-Whitman Eye Center and Nextech: A New Era in Eye Care

Key-Whitman Eye Center and Nextech: A New Era in Eye Care

Key-Whitman Eye Center Chooses Nextech for Improved Efficiency

Nextech, recognized as a leader in comprehensive technology solutions for specialty physician practices, has been selected by Key-Whitman Eye Center. This collaboration aims to automate various workflows, enhance speed to revenue, and significantly improve patient engagement and care across the center's multiple locations.

Transforming Operations with Technology

Dan Chambers, CEO at Key-Whitman Eye Center, expressed enthusiasm about the transition, stating the importance of streamlined operational processes. The embrace of Nextech's ophthalmology platform is not merely a tech upgrade; it's a critical step towards operational and financial efficiencies amid the center's growth.

Chambers emphasized how the platform allows visibility across clinical and ambulatory surgical center (ASC) operations. Such visibility is vital for enhancing clinical and patient outcomes, leading to a more collaborative environment for the management and clinical teams involved in evaluating and recommending integrated systems.

Nextech's Advanced Ophthalmology Platform

Built specifically for the complexities of eye care practices, Nextech's platform is known for its effective integration of electronic health record (EHR) and practice management systems. The result is a secure, user-friendly healthcare framework that automates clinical workflows, optimizes processes, and boosts the quality of the patient experience.

Supporting Multi-Location Practices

Rusty Frantz, the Chief Executive Officer of Nextech, highlighted a trend: an increasing number of multi-location eye care practices are reaching out for a unified technology solution. This technology provides these practices with a holistic view of their clinical operations, enabling expansion while maintaining quality and compliance.

Nextech's tools, designed to seamlessly fit into existing workflows, empower practices, allowing them to scale effectively and respond to the needs of their growing patient base.

A Look Ahead: Nextech at Upcoming Conference

As part of their ongoing commitment to serve the eye care community, Nextech will showcase their solutions at the AAO 2024 conference. Attendees can engage with their team at Booth 2308 to explore how Nextech can transform their operational landscape.

Key-Whitman Eye Center: A Legacy of Excellence

Key-Whitman Eye Center has long been regarded as a top-tier eye care facility. With 12 locations and 26 skilled doctors, it offers an extensive array of services, including advanced refractive surgery options and comprehensive eye care. Dr. Jeffrey Whitman leads the charge, guiding the center with pioneering practices and a profound commitment to patient health.

About Nextech: Innovation in Health Technology

Since its establishment in 1997, Nextech has focused on delivering innovative healthcare technology solutions tailored for specialty providers. Supporting over 16,000 physicians and more than 60,000 office personnel, Nextech's commitment is to fuel growth and improve the health care experience.

Contact Information

For inquiries, Ian Hoffman, the Chief Marketing Officer, is available at i.hoffman@nextech.com. Your questions about Nextech's services and vision for improving healthcare are welcomed.

Frequently Asked Questions

What is Nextech's role with Key-Whitman Eye Center?

Nextech provides a comprehensive ophthalmology platform aimed at automating workflows and enhancing patient care for Key-Whitman Eye Center.

How will the new platform improve efficiency?

The platform allows for better visibility across operations, facilitating improved clinical and patient outcomes.

Where can I learn more about Nextech?

Nextech will exhibit at the AAO 2024 conference, and more information can be found on their website.

Who leads Key-Whitman Eye Center?

Dr. Jeffrey Whitman serves as the Chief Surgeon and Medical Director, bringing over two decades of experience to the center.

How long has Nextech been in operation?

Nextech has been providing specialized technology solutions since 1997, helping countless providers enhance patient care.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BioVid Debuts AI to Mimic Physician Decision-Making

Updated Category News Views 47

Revolutionizing Understanding: BioVid Mimetics™ Now here's something that's shaking the research tree: BioVid's launching Mimetics™, and it's a big deal. They've come up with AI that can mirror how physicians think and decide. This ain't your run-of-the-mill tech stuff—it's groundbreaking in understanding physician decision-making. The Core: How Do Doctors Really...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 111

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
AZ Health Workers Step Up for Community Wellness

Updated Category News Views 4

Health Screenings: A Step Before the Hospital Sometimes it's the basics, like a plain old health screening, that can shift the tides from crisis to care. That's exactly where AZ Blue Health Choice and Zeihan ProHealth come into the picture, aiming to pin those health concerns before they spiral out of control. For your average Arizonan who finds healthcare as elusive as a...

Continue Reading
Enigmata Innovates AI Security with Finovifi Tie-Up

Updated Category News Views 94

Emerging AI Risks and Protective Measures AI in financial spaces is like walking a tightrope, there's potential but caution is crucial. Enter Enigmata, diving headfirst into this arena by shaking hands with the Finovifi Marketplace. Their aim? To bolster AI's promise without letting sensitive data slip through the cracks. Sentinel: A New Guard for Sensitive Data Let's not...

Continue Reading
Podcast Giants Converge in Tennessee for POD U Summit

Updated Category News Views 57

Nashville Becomes a Hotspot for Podcasters Amidst the strumming guitars and honky-tonk vibes of Nashville, Tennessee transformed into the epicenter of podcasting innovation thanks to Rebel Audio's inaugural summit, POD U. Here we had big names like Mike 'Big Mike' Majlak rubbing shoulders with sports experts and media moguls—a true concoction of voices shaping the...

Continue Reading
Home Insurance Gaps: Risky Assumptions Uncovered

Updated Category News Views 53

Unseen Threats to Homeownership Safety Liability gaps in insurance are like those stubborn stains on the carpet you keep missing—nearly invisible until you're flat on your face. In Alpharetta and Fulton County, homes aren't as secure from financial pitfalls as their charming façades suggest. So, what's the danger that folks are glossing over here? Hidden Dangers of...

Continue Reading
Americas Cardroom Smashes Prize Pools; Bahamas Up Next

Updated Category News Views 49

Ah, poker. Where dreams are won with a flick of the wrist and a well-placed bluff. This week, it was all eyes on Americas Cardroom’s Dual Venom PKOs, and let me tell you, they didn't just meet expectations—they chewed them up and spat them out like yesterday's jam. Two Titans Crowned in Poker Showdown The action wrapped up with a jaw-dropping $6,862,500 prize pool....

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 37

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
Savvy Moves: Avoiding Pitfalls When Buying Used Vans

Updated Category News Views 14

When you're eyeing a used work van, don't just kick the tires and jot down the mileage—there's a whole backyard BBQ checklist you need to chew through. Tony Collichio, the work van guru from Spencerport, lays it down for us, highlighting key questions to ask before pulling out the checkbook. And let me tell you, these aren’t your everyday 'how does it drive?' queries....

Continue Reading
Abbott's Oncodetect Test: Game-Changer for Cancer Recurrence

Updated Category News Views 4

Pioneering Progress in Colorectal Cancer Detection There's a new player in the world of cancer diagnostics, and it's setting a fresh standard. Abbott's Oncodetect test, featured at the ESMO Congress, has shown a profound leap in sensitivity—30 percent over the older whole-exome sequencing approach. For those doing the math on the stock charts, Abbott (NYSE: ABT) is...

Continue Reading

Top 5 Most Recently Viewed Articles

Clare Locke Advocates for Megan Thee Stallion in Defamation Case

Updated Category News Views 111

Clare Locke LLP Champions Megan Thee Stallion's Defamation Case Clare Locke LLP, a respected name in defamation law, has taken a bold step to support Megan Thee Stallion's pursuit of justice against Milagro Cooper. The firm has filed a motion for leave to present an amicus brief that specifically endorses Megan's effort to have a jury's defamation ruling reinstated. This...

Continue Reading
Bankers Signal Looming Economic Challenges Amid Uncertainty

Updated Category News Views 167

Bankers Signal Looming Economic Challenges Amid Uncertainty Interest rate fluctuations, credit quality, and tariffs are significant concerns for financial institutions. A recent survey highlights the anxiety among bankers regarding the economic climate and impending recession. Survey Highlights Economic Fears According to a survey from fintech IntraFi, which gathered...

Continue Reading
Dave Portnoy Questions Elon Musk Amid Tesla's Plummeting Stock

Updated Category News Views 162

Tesla's Stock Dilemma: Portnoy's Concerns Tesla’s stock, designated as TSLA, has recently experienced a significant decline, stirring up discussions among investors and enthusiasts alike. Dave Portnoy, the founder of Barstool Sports, has voiced his frustration regarding this situation, bringing forth some pointed questions about Elon Musk’s priorities. In a recent...

Continue Reading
Akropolis Group's Credit Rating Affirmed Amid Strategic Changes

Updated Category News Views 88

Akropolis Group’s Robust Credit Rating Amid Strategic Reassessments Renowned international credit rating agency S&P Global Ratings recently evaluated the financial outlook for Akropolis Group, a prominent player in the real estate development and management sector. This assessment took into account significant structural governance changes within the Vilniaus Prekyba...

Continue Reading
Arcutis Takes a Significant Step with ZORYVE Cream for Kids

Updated Category News Views 156

Arcutis Advances ZORYVE® Cream for Pediatric Use Arcutis Biotherapeutics, Inc. is making headlines with its recent submission of a supplemental New Drug Application (sNDA) aimed at expanding the use of ZORYVE (roflumilast) cream 0.3% to treat plaque psoriasis in children as young as 2 years old. If approved, ZORYVE would be the first topical PDE4 inhibitor specifically...

Continue Reading